Product
cetuximab
Aliases
Erbitux
Name
cetuximab
Target
RAS
FDA Approved
No
Ema approved
Status
0
9 clinical trials
1 abstract
16 indications
Indication
Advanced Solid TumorIndication
KRAS G12C Mutant Solid TumorsIndication
cancerIndication
Non-Small Cell LungIndication
Lung CancerIndication
Colorectal CancerIndication
Colorectal cancerIndication
CancerIndication
Solid TumorIndication
MelanomaIndication
Thyroid CancerIndication
GliomaIndication
Renal Cell CarcinomaIndication
Bladder CancerIndication
Gastric AdenocarcinomaIndication
NSCLCClinical trial
A Phase 1/2 Study of BMS-986315 as Monotherapy and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-01
Clinical trial
KontRASt-03: A Phase Ib/II, Multicenter, Open-label Platform Study of JDQ443 With Select Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationStatus: Recruiting, Estimated PCD: 2027-05-05
Clinical trial
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination With Pembrolizumab or Cetuximab in Patients With Advanced Solid Refractory/Resistant MalignanciesStatus: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A PHASE 1, OPEN-LABEL, MULTI-CENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EVIDENCE OF ANTI-TUMOR ACTIVITY OF PF-07284892 (ARRY-558) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS WITH ADVANCED SOLID TUMORSStatus: Active (not recruiting), Estimated PCD: 2024-06-18
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONSStatus: Recruiting, Estimated PCD: 2027-07-29
Clinical trial
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2026-08-19
Clinical trial
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)Status: Completed, Estimated PCD: 2021-02-19
Clinical trial
A Randomized, Multicenter, Open-label Phase II Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With KRAS Wild-type or Mutant Metastatic Colorectal CancerStatus: Completed, Estimated PCD: 2013-12-01
Clinical trial
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal and Genitourinary TumorsStatus: Completed, Estimated PCD: 2021-08-20
Abstract
Phase III FIRE-4 study (AIO KRK-0114): Influence of baseline liquid biopsy results in first-line treatment efficacy of FOLFIRI/cetuximab in patients with tissue RAS-WT mCRC.Org: Medical Department, Oncology Therapeutic Development, Charité Universitätsmedizin Berlin, Comprehensive Cancer Center at Ludwig Maximilian University of Munich, MVZ Gesundheitszentrum St. Marien GmbH,